---

title: "Longitudinal cytokine and multi-modal health data of an extremely severe ME/CFS patient with HSD reveals insights into immunopathology, and disease severity"
tags:
- ‚ûï 2025-12-25
- üß™ Biomarker
- ‚≠ê Landmark
- üíä Treatment
created: '2024-04-08'
published: '2024-04-08'

---


<details>
<summary>Jahanbani et al. (2024)</summary>

- **Authors:** Fereshteh Jahanbani, Justin Cyril Sing, Rajan Douglas Maynard, Shaghayegh Jahanbani, Janet Dafoe, Whitney Dafoe, Nathan Jones, Kelvin J. Wallace, Azuravesta Rastan, Holden T. Maecker, Hannes L. R√∂st, Michael P. Snyder, Ronald W. Davis.
- **Institutes:** Department of Genetics, Stanford University School of Medicine, Stanford, CA, United States; Department of Molecular Genetics, Donnelly Center, University of Toronto, Toronto, ON, Canada; Division of Immunology and Rheumatology, Stanford University School of Medicine, Veterans Affairs (VA) Palo Alto Health Care System, Palo Alto, CA, United States; ME/CFS Collaborative Research Center at Stanford, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, CA, United States; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Pulmonary and Critical Care Medicine, Institute of Immunity, Transplantation, and Infectious Diseases, Stanford University, Palo Alto, CA, United States.
- **Publisher:** Frontiers in Immunology
- **Link:** [DOI](https://doi.org/10.3389/fimmu.2024.1369295)

</details>


## Summary

This in-depth study of one extremely severe patient suggests that a specific type of immune imbalance, a Th2-dominant response involving mast cells and eosinophils, may drive severe symptoms like cognitive impairment and sensory overload. As the patient's health slightly improved, his immune markers shifted away from this Th2 profile, providing a potential biological explanation for changes in his condition. This finding strengthens the link between ME/CFS and related disorders like Mast Cell Activation Syndrome (MCAS) and Hypermobility Spectrum Disorder (HSD). The patient's improvement while taking low-dose Abilify (aripiprazole) üíä and Cortef (hydrocortisone) üíä, while not proof of efficacy, points toward potential therapeutic avenues targeting neuro-immune pathways that warrant further investigation.

## What was researched?

This study conducted an in-depth, four-year longitudinal investigation of a single, extremely severe ME/CFS patient with hypermobility spectrum disorder (HSD).  Researchers integrated longitudinal cytokine profiling with extensive health, clinical, pharmaceutical, and textual data to identify biological changes associated with a period of marginal symptom improvement.

## Why was it researched?

ME/CFS research is complicated by patient heterogeneity and a lack of approved diagnostics, and the most severely ill patients are often excluded from studies.  This research was motivated by the need to understand the immunopathology of severe ME/CFS by focusing on a single patient during a phase of slight improvement, aiming to uncover insights into disease mechanisms, severity, and potential therapeutic strategies.

## How was it researched?

This was an N-of-1 longitudinal case study conducted over four years on an extremely severe, bedridden male ME/CFS patient with HSD.  Researchers collected nine blood samples during a period of marginal health improvement and performed multiplex cytokine profiling.  This biological data was integrated with comprehensive clinical records, medication logs, and textual analysis of the patient's blog posts using natural language processing to identify correlations between molecular changes and symptom severity.

## What has been found?

The study found that the patient's marginal health improvement, particularly in cognitive function and sensory intolerance, correlated with a reduction in Th2-type cytokines and decreased activity of mast cells and eosinophils.  This suggests a Th2-dominant immune profile is associated with greater disease severity in this case.  The analysis also implicated the BCL6 and TP53 pathways in ME/CFS pathology.  The patient's improvement was observed after he began taking low-dose Abilify (aripiprazole) üíä and increased his dose of Cortef (hydrocortisone) üíä, while the dosage of other medications was reduced.

## Discussion

The authors acknowledge that the primary limitation is this being a single-patient study (N-of-1), which means the findings may not be generalizable to the broader ME/CFS population.  However, they argue that this deep, longitudinal approach on an extremely severe individual provides invaluable, high-resolution insights often missed in larger cross-sectional studies and highlights the importance of including this cohort in research.

## Conclusion & Future Work

The authors conclude that integrating longitudinal multi-modal data is a valuable approach for understanding ME/CFS.  They suggest that aberrant Th2-type cytokines and synergistic activities between mast cells and eosinophils are significant in ME/CFS pathogenesis, especially in severe cases, and may represent a shared mechanism with comorbidities like HSD and MCAS.  Future research should further explore these immune pathways, the roles of regulators like BCL6 and TP53, and the potential of low-dose drugs with partial agonist activity as treatments.
